Rare Disease Diagnostics Market to be dominated by Growing Incidence of Rare Disorders through 2027
Growing prevalence of rare
diseases and rise in technological advancements to drive the rare disease
diagnostics market in the forecast period, 2023-2027.
According to TechSci Research report, “Rare
Disease Diagnostics Market - Global Industry Size, Share, Trends, Opportunity,
and Forecast, 2017-2027”, the global rare disease diagnostics market is
anticipated to grow at a significant rate in the forecast period, 2023-2027. The
rising incidence of rare disorders, rising awareness of diagnosis of rare
diseases, and extensive research and development are the primary factors
driving the demand for the global rare disease diagnostics market. Growing adoption
of advanced technology and declining sequencing cost, expanding patient
registry for rare disease, and heavy investments in healthcare sector are expected
to influence the market demand. Also, the growing launch of programs & new
product development in rare disease diagnosis is also a key factor for
increasing the growth of the Rare Disease Diagnostics market, globally.
However, the growing launch of programs & new
product development in rare disease diagnosis may hamper the growth of the
global Rare Disease Diagnostics market.
Browse over XX market
data Figures spread through 110 Pages and an in-depth TOC on "Rare Disease Diagnostics Market"
The global rare disease
diagnostics market is segmented into indication, trait type, test type,
technology, sample type, end user and company.
Based on indication, the
market is divided into gastroenterology disease, endocrine & metabolism
disorders disease, cardiovascular disorders, hematology & oncology disease,
and others. The endocrine & metabolism disorders disease segment is expected
to hold the largest market share. This is attributed to the high prevalence of
rare diseases, and large patient pool.
Based on trait type, the market is
divided into inherited and acquired.
The inherited segment is expected to witness largest
market share. This is attributed to rising world population, unhealthy choices,
and sedentary life.
Based on test type, the market is segmented
into genetic tests, general lab tests, diagnostic imaging, and others. The genetic tests segment is
expected to witness largest market share. This is attributed to the high
adoption in research & clinical settings.
Based on technology, the market is
divided into next generation sequencing, whole genome sequencing, whole exome
sequencing, microarrays, and others. The
next generation sequencing segment is expected to
witness largest market share. This is attributed to wide availability and
adoption of NGS-based gene panels for cancer, cardiovascular disease, neurologic
disease, psychiatric disorders, and other related disease.
Based on sample type, the market is
divided into DNA sample, blood sample, saliva sample, and others. The DNA sample segment is
expected to witness largest market share. This is attributed to its easier and
multiple options to provide it.
Based on end user, the market
is divided into hospitals & clinics, academic & research institutes, and
others. The academic & research institutions segment is anticipated to
grow during the forecast period. This is attributed to basic research which is
carried out at academia, and strong scientific and technological knowledge
available with academic research laboratories.
Major operating companies
operating in global rare disease diagnostics market are:
- Agilent Technologies, Inc.
- Illumina, Inc.
- QIAGEN NV
- PerkinElmer, Inc
- Quest Diagnostics, Inc.
- CENTOGENE N.V.
- 23andMe, Inc.
- 3billion, Inc.
- Eurofins Scientific SE
- Invitae Corporation
Download Free Sample Report
Customers can also
request for 10% free customization on this report.
“North America region dominates the
market in 2021 and is expected to maintain its dominance in the coming years
due high incidence of rare diseases. The presence of a substantial number of
R&D facilities for ultra-rare diseases, presence of a large number of leading players, strongly
established research infrastructure, extensive investments in the diagnosis of
disease, and the availability of appropriate technology in the region is
another key factor. Also, owing to growing
adoption of acquisitions and in the region are expected to propel the global rare
disease diagnostics market growth till 2027” said Mr. Karan Chechi, Research
Director with TechSci Research, a research based global management consulting
firm.
“Rare Disease Diagnostics
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
2017-2027 Segmented By Indication
(Gastroenterology Disease, Endocrine & Metabolism Disorders Disease,
Cardiovascular Disorders, Hematology & Oncology Disease, Others), By Trait
Type (Inherited v/s Acquired), By Test Type (Genetic Tests, General Lab Tests,
Diagnostic Imaging, Others), By Technology (Next Generation Sequencing, Whole
Genome Sequencing, Whole Exome Sequencing, Microarrays, Others), By Sample Type
(DNA Sample, Blood Sample, Saliva Sample, Others), By End User (Hospitals &
Clinics, Academic & Research Institutes, Others), By company and By Region”, has evaluated the future growth potential of global rare
disease diagnostics market and provides statistics & information on market
size, structure, and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in global rare
disease diagnostics market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com